Allspring Global Investments’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.01M Sell
24,054
-5,862
-20% -$612K ﹤0.01% 996
2026
Q1
$3.1M Buy
29,916
+25,931
+651% +$2.3M 0.01% 964
2025
Q4
$347K Buy
+3,985
New +$326K ﹤0.01% 1476
2025
Q1
– Sell
-5,975
Closed -$231K – 1802
2024
Q4
$231K Sell
5,975
-97,867
-94% -$4.27M ﹤0.01% 1647
2024
Q3
$4.67M Buy
103,842
+103,414
+24,162% +$4.18M 0.01% 962
2024
Q2
$14.8K Sell
428
-1,542
-78% -$45.2K ﹤0.01% 2164
2024
Q1
$57K Sell
1,970
-563
-22% -$15.3K ﹤0.01% 1929
2023
Q4
$58.1K Sell
2,533
-5,973
-70% -$105K ﹤0.01% 1868
2023
Q3
$142K Sell
8,506
-167,023
-95% -$3.24M ﹤0.01% 1865
2023
Q2
$4.85M Sell
175,529
-48,135
-22% -$1.2M 0.01% 1011
2023
Q1
$5.14M Buy
223,664
+217,761
+3,689% +$3.66M 0.01% 985
2022
Q4
$64.4K Sell
5,903
-5,784
-49% -$48.8K ﹤0.01% 2239
2022
Q3
$98K Buy
11,687
+1,375
+13% +$13K ﹤0.01% 2093
2022
Q2
$81K Sell
10,312
-16,994
-62% -$205K ﹤0.01% 2123
2022
Q1
$646K Buy
27,306
+1,935
+8% +$54.5K ﹤0.01% 2111
2021
Q4
$867K Buy
+25,371
New +$802K ﹤0.01% 2026

Other funds holding PTGX

Allspring Global Investments's PTGX Position: Q2 2026 in Review

Allspring Global Investments reduced its Protagonist Therapeutics (PTGX) stake by 20% in Q2 2026, selling an estimated $612K and leaving 24,054 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Allspring Global Investments first reported a position in PTGX in Q4 2021 and has held it in 16 quarters since. The position peaked at $5.14M in Q1 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Allspring Global Investments held 24,054 shares of Protagonist Therapeutics worth $3.01M as of Q2 2026.
  • Allspring Global Investments sold 5,862 Protagonist Therapeutics shares in Q2 2026, an estimated $612K.
  • Protagonist Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #996 holding.
  • Allspring Global Investments first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Allspring Global Investments's Protagonist Therapeutics position peaked at $5.14M in Q1 2023.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.